NCT05679570Recruiting

Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)

Name: Clinical Trial NCT05679570
Creator: International University of Health and Welfare
Keywords: Pulmonary Arterial Hypertension, Satralizumab (Genetical Recombination), Phase 2, drug, clinical trial, Japan

Satralizumab,an Anti-IL-6 Receptor Antibody, in the Treatment of Pulmonary Arterial Hypertension; Safety and Efficacy Evaluation in Japan -Multicenter, Investigator-sponsored Trial-

International University of Health and WelfarePhase 2ClinicalTrials.govdrug

Verified

Study focus

Disease/Condition: Pulmonary Arterial Hypertension
Drug/Device/Intervention: Satralizumab (Genetical Recombination)
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: International University of Health and Welfare
Location: Chiba,Fukuoka,Kobe,Kurume,Mitaka,Nagoya,Sapporo,Tokyo,Tokyo, Japan

Timeline & enrollment

Phase: Phase 2
Start date: Jul 12, 2022
End date: Sep 30, 2024
Enrollment: 24 participants

Primary outcome

Percent change in total pulmonary vascular resistance (PVR) from baseline to 24 weeks.

Summary

Examine the efficacy of satralizumab in patients with pulmonary arterial hypertension (PAH) with immune-responsive phenotype serum interleukin-6 (IL-6) ≥ 2.73 pg/mL who have an inadequate response to existing drugs.

ICD-10 classifications

Primary pulmonary hypertensionOther secondary pulmonary hypertensionPulmonary heart disease and diseases of pulmonary circulationStenosis of pulmonary arteryPulmonary heart disease, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05679570
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05679570 through Pure Global AI's free database. This Phase 2 trial is sponsored by International University of Health and Welfare and is currently Recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.